Clinical trials: Coronavirus (SARS-CoV)
Covid19, SARS-CoV Infection
Proxalutamide Treatment for COVID-19 Female Outpatients
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Trial name
- NCT04853134
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
SARS CoV 2 Infection
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.
- Trial name
- ICASARS (NCT05407597)
- Testing
- Icatibant, 0.9% Sodium Chloride Injection
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Belfast Health and Social Care Trust
SARS-CoV Infection, Covid19
International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)
The International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global), is an international registry of approximately 10,000 healthcare workers in low- and middle-income countries experiencing increasing…
- Trial name
- NCT04626076
- Testing
- Comparative Observational Cohort Study
- Where
- Pakistan
- Volunteers
- 6,808 people, healthy volunteers welcome
- Sponsor
- Certara
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Corona Virus Infection, SARS-CoV Infection
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
Study Objective: To test if early preemptive hydroxychloroquine therapy can prevent disease progression in persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom severity.
- Conditions
- Corona Virus Infection, SARS-CoV Infection, Coronavirus
- Trial name
- NCT04421664
- Testing
- Hydroxychloroquine
- Where
- 8 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Covid19, Corona Virus Infection
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC)…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS
- Trial name
- ULSC (NCT04494386)
- Testing
- Umbilical Cord Lining Stem Cells (ULSC)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Restem, LLC.
Infectious Disease, SARS-CoV Infection
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
The benefit of the research is to provide information regarding the efficacy and safety of Favipiravir plus the Standard of Care (SoC) for mild-moderate COVID-19 patients to be a reference for policy recommendations regarding the…
- Conditions
- Infectious Disease, SARS-CoV Infection, Covid19
- Trial name
- FVR (NCT04613271)
- Testing
- Favipiravir, Azithromycin
- Where
- 3 sites in Indonesia
- Volunteers
- 130 people
- Sponsor
- Ina-Respond
Coronavirus as the Cause of Diseases Classified Elsewhere
CoV-ICU Score, Intensive Care Unit, SARS-CoV-2
In the course of COVID disease, some patients need intensive care treatment. We aim to find an answer to the question of whether the patient's CRP, ferritin, D-dimer, Oxygen Saturation, lymphocyte count, and body mass index can…
- Trial name
- NCT04383483
- Testing
- COVICU
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Coronavirus Infection, SARS-CoV 2
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults…
- Trial name
- NCT04447781
- Testing
- INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer
- Where
- 2 sites in South Korea
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
COVID-19, SARS CoV 2 Infection
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
The Post-Acute Sequelae of SARS-CoV-2 (PASC) Autopsy Study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of…
- Trial name
- NCT05292274
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- NYU Langone Health
Anosmia, SARS CoV 2 Infection
Anosmia and Covid-19
Our study aims to determine the prevalence of anosmia in patients SARS-Cov-2/Covid-19 infection (both by symptom reporting and smell testing), the efficacy of early olfactory training for the treatment of anosmia caused by…
- Trial name
- COVANOS (NCT05246059)
- Testing
- Olfactory Training
- Where
- 4 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Covid-19, SARS-CoV Infection
Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database
Analysing ths spread of COVID-19 epidemics in a timely manner is key to implementing public health control strategies. The investigators propose to analyse a large set of laboratory SARS-CoV-2 RT-PCR data to explore potential…
- Trial name
- CovPCR (NCT04738331)
- Where
- France
- Volunteers
- 10,000,000 people
- Sponsor
- University Hospital, Montpellier
Covid19
COVID-19 Personal Protective Equipment for Vaccinated Health Workers and Convalescents
The aim of the trial is to assess the safety of using simplified personal protective equipment (PPE) for vaccinated or COVID-19 convalescent healthcare workers working in COVID-19 ICU or COVID-19 wards.
- Trial name
- NCT06158724
- Testing
- Personal Protective Equipment
- Where
- Slovenia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
SARS-CoV Infection, Systemic Disease
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease…
- Conditions
- SARS-CoV Infection, Systemic Disease, Systemic Lupus Erythematosus, Sjogren's Syndrome
- Trial name
- NCT04530461
- Testing
- Serological test
- Where
- Tunisia
- Volunteers
- 200 people
- Sponsor
- faida agili
Covid19, SARS-CoV Infection
Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2
The investigators aim to develop expert consensus statements on infection control management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in intensive care units (ICU).
- Conditions
- Covid19, SARS-CoV Infection, SARS Pneumonia, Coronavirus Infection
- Trial name
- IC-COVID-19 (NCT04665960)
- Where
- United Arab Emirates
- Volunteers
- 35 people
- Sponsor
- NMC Specialty Hospital
Covid19, SARS-CoV Infection
Italian Web-based Cross-sectional Survey on COVID-19
The outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that started in late December 2019 in the Hubei province of China caused millions of cases worldwide in just a few months, and evolved into a real…
- Conditions
- Covid19, SARS-CoV Infection, Survey, Family Life, Epidemic Disease
- Trial name
- EPICOVID19 (NCT04471701)
- Testing
- Environmental exposure and clinical features
- Where
- Italy
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Institute of Biomedical Technologies-National Research Council, Italy
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
COVID-19, Neuro-Degenerative Disease
Randomised Clinical Trial to Evaluate the Efficacy of an Online Cognitive Rehabilitation Programme (COPERIA-COG) for Patients With Persistent COVID-19
The pandemic caused by SARS-CoV-2 infection has led to the emergence of diffuse and heterogeneous persistent symptoms in addition to the well-known acute symptoms, which have come to be referred to as persistent COVID.
- Conditions
- COVID-19, Neuro-Degenerative Disease, Psychological, SARS CoV 2 Infection
- Trial name
- COPERIA-COG (NCT05629897)
- Testing
- Sessions of cognitive stimulation
- Where
- 2 sites in Spain
- Volunteers
- 88 people
- Sponsor
- Fundacin Biomedica Galicia Sur